[Farewell to the intra-aortic balloon pump?].
The intra-aortic balloon pump (IABP) has been a reliable friend in the catheterization laboratory and operating room. This good old friend of the cardiologist and cardiothoracic surgeon is about to disappear from the clinical scene. For more than 5 decades, it has largely been deployed for acute myocardial infarction and cardiogenic shock. Its more recent failure to demonstrate efficacy for cardiogenic shock will herald its demise. It may not disappear completely but its usage will become extremely limited. The lesson we have learned from the IABP history and other therapies is that we should never trust surrogate endpoints such as cardiac (power) output when it comes to cardiogenic shock. Newer devices should be tested in properly randomized controlled clinical trials before worldwide adoption.